
Sharekhan

by BNP PARIBAS

Sector: Consumer Goods Company Update




Company details

| Market cap: | Rs. 4,17,592 cr |
|----------------------------|-----------------|
| 52-week high/low: | Rs. 2,187/1,650 |
| NSE volume: (No of shares) | 14.3 lakh |
| BSE code: | 500696 |
| NSE code: | HINDUNILVR |
| Sharekhan code: | HINDUNILVR |
| Free float: (No of shares) | 71.0 cr |

Shareholding (%)

| Promoters | 67.2 |
|-----------|------|
| FII | 12.9 |
| DII | 6.7 |
| Others | 13.3 |

Price chart



Price performance

| (%) | 1m | 3m | 6m | 12m | | |
|------------------------------|------|------|-----|------|--|--|
| Absolute | -4.7 | 7.7 | 9.2 | 7.3 | | |
| Relative to Sensex | -7.0 | -5.1 | 2.2 | -7.0 | | |
| Sharekhan Research Bloomherg | | | | | | |

Hindustan Unilever

Recovery to take time, long-term growth story intact

Rural demand continued to remain sluggish in India with rural sales moderating to 0.5x urban sales in Q2FY2020. Demand in rural India continues to remain slow due to lower income in the hands of the rural population. In view of sustained slowdown in rural India, Unilever PLC has reduced its revenue guidance for CY2019 and H1CY2020. (Hindustan Unilever Limited's [HUL] contribution is higher in Unilever's Asia-Pacific region). HUL's management also indicated in the Q2FY2020 conference call that slowdown is expected to persist and recovery in demand would take another two to three quarters. However, HUL has undertaken various measures such as partnering with banks and financial partners and offering additional credit to wholesalers in rural markets to ease out liquidity concerns in trade channels. These, along with better rabi crop production in the backdrop of better monsoon and stability in the macro environment, would help in demand revival by H1FY2021 (largely in Q2FY2021). Hence, we are cutting our FY2020E and FY2021E estimates by "3% each. We expect the volume growth trajectory to get back to 6-8% in the near to medium term.

Benign input prices and operating efficiencies to help margin expansion to sustain: Raw-material prices including palm oil prices remained benign in H1FY2020. HUL has taken pricing cuts in its core soaps category to see some improvement in sales volume. However, sales of the personal care category would continue to remain under pressure due to sustained slowdown. Thus, overall volume growth is expected to sustain at mid-single digit in H2FY2020. On the other hand, benign input prices and operating efficiencies will help operating margins to sustain on high base in H2FY2020. Despite slowdown in the domestic market, management has maintained its thrust on new launches and premiumisation to drive its long-term growth. In recent times, new launches such as Love & Care and Magic rinse powder are receiving good response. Oral care is regaining some momentum, led by freshness (Close-up) and naturals (Ayush) categories with region-specific media communication. We believe this will help HUL to achieve sustainable volume growth of 6-8% in the near to medium term in the backdrop of normal demand environment.

Our Call

Valuation – Maintain Buy with a revised PT of Rs. 2,185: We have reduced our earnings estimates for FY2020E and FY2021E by "3% each to factor in sustained slowdown in the demand environment, especially in rural geographies. We have introduced FY2022E estimates in this note. The stock has corrected by 10% in the past one month, which factors in the near-term headwind of slower revenue growth in rural markets. Hence, there is very limited downside risk from the current level. However, the long-term growth story of HUL is intact. Hence, we maintain our Buy recommendation on the stock with a revised price target (PT) of Rs. 2,185 (valuing the stock at 49x average of FY2021-FY2022 earnings estimates).

Key Risks

Any sustained slowdown in volume growth and margin decline due to increased input prices would be key risks to our earnings estimates.


| Revenue 35,218 38,224 40,566 45,702 51,755 OPM (%) 20.7 22.6 24.8 25.3 25.7 Adjusted PAT 5,287 6,199 7,395 8,791 10,484 % YoY growth 24.4 17.3 19.3 18.9 19.3 Adjusted EPS (Rs.) 24.5 28.7 34.2 40.7 48.5 P/E (x) 78.8 67.2 56.3 47.4 39.7 P/B (x) 58.9 54.4 42.3 31.0 22.2 EV/EBIDTA (x) 56.4 47.5 40.6 34.8 29.8 RoNW (%) 77.9 84.2 84.5 75.5 65.2 | Valuation | | | | | Rs cr |
|--|--------------------|--------|--------|--------|--------|--------|
| OPM (%) 20.7 22.6 24.8 25.3 25.7 Adjusted PAT 5,287 6,199 7,395 8,791 10,484 % YoY growth 24.4 17.3 19.3 18.9 19.3 Adjusted EPS (Rs.) 24.5 28.7 34.2 40.7 48.5 P/E (x) 78.8 67.2 56.3 47.4 39.7 P/B (x) 58.9 54.4 42.3 31.0 22.2 EV/EBIDTA (x) 56.4 47.5 40.6 34.8 29.8 RoNW (%) 77.9 84.2 84.5 75.5 65.2 | Particulars | FY18 | FY19 | FY20E | FY21E | FY22E |
| Adjusted PAT 5,287 6,199 7,395 8,791 10,484 % YoY growth 24.4 17.3 19.3 18.9 19.3 Adjusted EPS (Rs.) 24.5 28.7 34.2 40.7 48.5 P/E (x) 78.8 67.2 56.3 47.4 39.7 P/B (x) 58.9 54.4 42.3 31.0 22.2 EV/EBIDTA (x) 56.4 47.5 40.6 34.8 29.8 RoNW (%) 77.9 84.2 84.5 75.5 65.2 | Revenue | 35,218 | 38,224 | 40,566 | 45,702 | 51,755 |
| % YoY growth 24.4 17.3 19.3 18.9 19.3 Adjusted EPS (Rs.) 24.5 28.7 34.2 40.7 48.5 P/E (x) 78.8 67.2 56.3 47.4 39.7 P/B (x) 58.9 54.4 42.3 31.0 22.2 EV/EBIDTA (x) 56.4 47.5 40.6 34.8 29.8 RoNW (%) 77.9 84.2 84.5 75.5 65.2 | OPM (%) | 20.7 | 22.6 | 24.8 | 25.3 | 25.7 |
| Adjusted EPS (Rs.) 24.5 28.7 34.2 40.7 48.5 P/E (x) 78.8 67.2 56.3 47.4 39.7 P/B (x) 58.9 54.4 42.3 31.0 22.2 EV/EBIDTA (x) 56.4 47.5 40.6 34.8 29.8 RoNW (%) 77.9 84.2 84.5 75.5 65.2 | Adjusted PAT | 5,287 | 6,199 | 7,395 | 8,791 | 10,484 |
| P/E (x) 78.8 67.2 56.3 47.4 39.7 P/B (x) 58.9 54.4 42.3 31.0 22.2 EV/EBIDTA (x) 56.4 47.5 40.6 34.8 29.8 RoNW (%) 77.9 84.2 84.5 75.5 65.2 | % YoY growth | 24.4 | 17.3 | 19.3 | 18.9 | 19.3 |
| P/B (x) 58.9 54.4 42.3 31.0 22.2 EV/EBIDTA (x) 56.4 47.5 40.6 34.8 29.8 RoNW (%) 77.9 84.2 84.5 75.5 65.2 | Adjusted EPS (Rs.) | 24.5 | 28.7 | 34.2 | 40.7 | 48.5 |
| EV/EBIDTA (x) 56.4 47.5 40.6 34.8 29.8 RoNW (%) 77.9 84.2 84.5 75.5 65.2 | P/E (x) | 78.8 | 67.2 | 56.3 | 47.4 | 39.7 |
| RoNW (%) 77.9 84.2 84.5 75.5 65.2 | P/B (x) | 58.9 | 54.4 | 42.3 | 31.0 | 22.2 |
| | EV/EBIDTA (x) | 56.4 | 47.5 | 40.6 | 34.8 | 29.8 |
| | RoNW (%) | 77.9 | 84.2 | 84.5 | 75.5 | 65.2 |
| RoCE (%) 104.2 113.2 106.8 95.8 84.8 | RoCE (%) | 104.2 | 113.2 | 106.8 | 95.8 | 84.8 |

Source: Company; Sharekhan estimates




Financials in charts

Volume growth came in at 5% in Q2



Source: Company, Sharekhan Research

GPM and OPM improved significantly y-o-y




Source: Company, Sharekhan Research

Ad spends maintained




Source: Company, Sharekhan Research

Key categories moderated due to slowdown




Source: Company, Sharekhan Research

Revenue & PAT grew @ CAGR of 5.6% & 12.6%



Source: Company, Sharekhan Research

Return ratios remained strong



Source: Company, Sharekhan Research




Outlook

Volume growth to remain in low single digit in H2FY2020: Rural sales stood at 0.5x of urban sales in Q2FY2020, which continue to put pressure on the consumer goods industry's growth. Demand in rural India continues to remain sluggish due to lower income in the hands of the rural population. HUL's volume growth in H1FY2020 stood at 5% in the domestic business and we expect it to remain at 5-6% in the near term. However, benign input prices and operating efficiencies will help margins to remain high on a y-o-y basis.

Valuation

Maintain Buy with a revised PT of Rs. 2,185: We have reduced our earnings estimates for FY2020E and FY2021E by $^{\sim}3\%$ each to factor in sustained slowdown in the demand environment, especially in rural geographies. We have introduced FY2022E estimates in this note. The stock has corrected by 10% in the past one month, which factors in the near-term headwind of slower revenue growth in rural markets. Hence, there is very limited downside risk from the current level. However, the long-term growth story of HUL is intact. Hence, we maintain our Buy recommendation on the stock with a revised price target (PT) of Rs. 2,185 (valuing the stock at 49x average of FY2021-FY2022 earnings estimates).

One-year forward P/E (x) band



Source: Company; Sharekhan Research

Peer Comparison

| Particulars | | P/E (x) | | | EV/EBIDTA (x) | | | RoCE (%) | | |
|---------------|------|---------|-------|------|---------------|-------|-------|----------|-------|--|
| Particulars | FY19 | FY20E | FY21E | FY19 | FY20E | FY21E | FY19 | FY20E | FY21E | |
| Nestle India* | 83.2 | 70.1 | 57.0 | 50.7 | 47.8 | 39.8 | 70.3 | 67.1 | 67.9 | |
| ITC | 24.3 | 19.7 | 17.8 | 15.9 | 14.3 | 12.7 | 27.8 | 27.7 | 28.4 | |
| HUL | 67.2 | 56.3 | 47.4 | 47.5 | 40.6 | 34.8 | 113.2 | 106.8 | 95.8 | |

Source: Company, Sharekhan estimates

*Values for Nestle India are for CY2018, CY2019E and CY2020E



About company

HUL is India's largest FMCG company with a strong presence in the home care and beauty and personal care categories. The company is a subsidiary of Unilever Plc (that holds a 67% stake in HUL), the world's largest consumer goods company present across 190 countries. With over 40 brands spanning 12 distinct categories such as personal wash, fabric wash, skin care, hair care, oral care, deodorants, colour cosmetics, beverages, ice creams, frozen desserts and water purifiers, HUL is part of the everyday life of millions of consumers across India. The company's portfolio includes leading brands such as Lux, Lifebuoy, Surf Excel, Rin, Wheel, Fair & Lovely, Pond's, Vaseline, Lakmé, Dove, Clinic Plus, Sunsilk and Axe. HUL reported revenue of Rs. 38,224 crore and OPM of 22.6% in FY2019.

Investment theme

HUL has a leadership position in highly penetrated categories such as soaps, detergents and shampoos in India. Sustaining product innovation, entering into new categories, premiumisation and increasing distribution network remain some of the key revenue drivers for the company. The recent acquisition of GSK Consumer will make HUL a formidable play in the health food drinks segment and will enhance the growth prospects of its relatively small food business. A strong financial background, robust cash-generation ability and leadership position in some key categories give HUL an edge over other companies and, hence, justify the stock's premium valuation.

Key Risks

- Slowdown in the demand environment: Any slowdown in demand (especially in rural India) would affect sales of key categories, resulting in moderation of sales volume growth.
- Increased input prices: Palm oil and crude derivatives such as linear alkyl benzene are some of the key raw materials used by HUL. Any significant increase in the prices of some of these raw materials would affect profitability and earnings growth.
- Increased competition in highly penetrated categories: Increased competition in highly penetrated categories such as soaps and detergents would act as a threat to revenue growth.

Additional Data

Key management personnel

| Sanjiv Mehta | Chairman and Managing Director |
|-------------------|---|
| Srinivas Pathak | Executive Director, Finance & IT and CFO |
| Pradeep Bannerjee | Executive Director, Supply Chain |
| Dev Bajpai | Executive Director, Legal and Corporate Affairs and Company Secretary |

Source: Company

Top 10 shareholders

| Sr. No. | Holder Name | Holding (%) | | |
|---------|-------------------------------------|-------------|--|--|
| 1 | Unilever PLC | 51.5 | | |
| 2 | Brooke Bond Group Ltd | 4.9 | | |
| 3 | Unilever Overseas Holdings Ltd | 4.1 | | |
| 4 | Unilever UK & CN Holdings Ltd | 2.8 | | |
| 5 | Brooke Bond South India Estates Ltd | 2.4 | | |
| 6 | Brooke Bond Assam Estates Ltd | 1.5 | | |
| 7 | Vanguard Group Inc | 1.2 | | |
| 8 | BlackRock Inc | 1.1 | | |
| 9 | Nomura Holdings Inc | 0.7 | | |
| 10 | SBI Funds Management Pvt Ltd | 0.7 | | |

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.



Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com; For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.